Sun Pharmaceutical Industries has elevated Aalok Shanghvi, son of the drugmaker’s founder promoter Dilip Shanghvi, as the Chief Operating Officer.
Aalok (40 years), continues as Whole-time Director and Executive Vice-President, Emerging Markets, Global Generic R&D, Global Business Development (Generics), Operations and API (active pharmaceutical ingredients).
Having joined Sun Pharma in 2006, Aalok handled roles in marketing, research and development, project management, purchase and communications, the company said. In 2014, he became the Head of Emerging Markets, across 80 countries covering Africa, the Middle East, APAC, Eastern Europe, CIS, and LATAM. The emerging markets business contributes about 18 percent to Sun Pharma’s global revenues.
Later, he took additional charge of the company’s Global Generic R&D, Global Business Development (Generics), Operations and the API (Active Pharmaceutical Ingredients) functions. He has been serving as the Whole-time Director of Sun Pharma since June 2023. Aalok majored in Cellular and Molecular Biology at the University of Michigan – Ann Arbor, the company said.